Electronic Labeling Study By GAO Yields “No Consensus,” Avoids Cost Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
In study mandated by FDASIA, GAO says there are advantages and disadvantages to switching to an electronic-only system for distributing drug label information, but offers no conclusions.
You may also be interested in...
Will Antimicrobial Breakpoint Changes Signal Shift To Online Labeling Updates?
FDA must place antimicrobial breakpoints that usually appear in labeling on a website so they can be more regularly updated. CDER Director Woodcock said that could become a precedent for other electronic labeling changes.
Priority Review Vouchers, FDA Funding Win In Omnibus Budget Deal
FY 2016 funding bill is much higher than House and Senate appropriations committee totals.
Electronic Prescribing Information: Proposed Rule May Not Completely Eliminate Paper
FDA expresses concerns about providing both paper and electronic versions of prescribing information to health care providers but seeks comments on dual systems anyway.